IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$42.25 USD
-0.14 (-0.33%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $42.23 -0.02 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 161 - 172 ( 172 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
MAT2A Candidate Nominated and IND Submission Remains on Track for 4Q20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Results; IDE196 Proceeding to Combination Trial Initiation in Mid-2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Update: COVID-19 Impact Minimal with Key Milestones Expected in 2H20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Update: Cash Position - 2020 Catalysts of Covered Companies
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
A Good Idea for Investors; Initiating With a Buy Rating and $13 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q19 Update: Pipeline Advances and Clinical Data Readout Expected In 2H20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We are sending out a reminder about our 33rd Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $12 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z